An2 Therapeutics Inc (ANTX) Stock Price, Quote & News

Company Profile

AN2 Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics. The company's initial candidate includes epetraborole, which is phase 3 clinical trial as a once-daily oral treatment for patients with non-tuberculous mycobacterial lung disease, as well as studying for the treatment of acute melioidosis. It also develops AN2-502998 (AN15368), an investigational, boron-based small molecule in development for the treatment of chronic Chag...

Industry: Biotechnology

Sector: Healthcare

Phone: 650 331 9090

Website: www.an2therapeutics.com

Address:

1800 El Camino Real, Suite D, Menlo Park, United States

OfficialStocktwitsUser Jan. 6 at 4:40 AM

$ANTX RSI: 30.30, MACD: -0.0098 Vol: 0.04, MA20: 1.13, MA50: 1.14 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.

0 · Reply

SuperGreenToday Dec. 31 at 5:52 PM

$ANTX

0 · Reply

SprintShares Dec. 26 at 4:58 PM

$ANTX Market structure is quietly punishing unfocused strategies. Efficiency initiatives must translate into measurable productivity. Momentum could expand quickly if milestones stop slipping. Durable value creation requires execution to catch up with vision.

0 · Reply

TheRealShortSqueezy Dec. 15 at 3:26 PM

$HYFT: Riding the AI Biotech Wave Into Its Next Stage of Growth With AI fueling a new era of biotech breakthroughs, MindWalk is perfectly positioned, merging deep tech and biology to accelerate discoveries the entire sector has been waiting for. 📞 Conference Call Coming Up As the call approaches, investors are looking for clarity on HYFT’s accelerating momentum. Key topics expected to be discussed include: ➖ Record Q2 revenue growth and margin expansion ➖ Updates on the GLP-1 + longevity programs and dengue vaccine progress ➖ Strategic direction heading into the mid-January JPM update 💰 Strengthened by September’s Strategic Move On Sept 15, MindWalk sold its Netherlands operations, unlocking over $14M. That capital is now being directed into HYFT’s core BioNative AI platform and wet lab programs. Communicated Disclaimer : https://tinyurl.com/58pvrf5j Sector Peers: $FATE $IGMS $ANTX $CABA

1 · Reply

TheRealShortSqueezy Dec. 15 at 1:47 PM

$HYFT: RECORD Growth + Big Pipeline Wins Just Dropped 🗞️📰 MindWalk Holdings Corp just delivered its strongest quarter yet, combining major financial momentum with breakthrough AI driven pipeline progress. 📈 Financial Highlights: ➖ Revenue $4.1M (+54% YoY, +30% QoQ) ➖Gross margin 65% (up from 51%) ➖Gross profit +94% YoY ➖ $16.5M cash for platform + pipeline expansion 🧬 Pipeline Highlights: ➖ GLP-1: AI-designed agonist outperforming semaglutide ➖ Added longevity pathway → dual-pathway metabolic program 💥 Strategic Progress: ➖ Rebrand completed + new CFO/CBO ➖ Netherlands sale → $14.3M redirected to AI + wet lab programs 🔥 Next Catalyst: ➖ Mid-January pipeline + partnership update at JPM Healthcare Conference Record growth, stronger margins, and a loaded pipeline, $HYFT’s momentum is accelerating fast. Communicated Disclaimer : https://tinyurl.com/58pvrf5j Sector Peers: $IGMS $ANTX $CABA $ENTX

0 · Reply

d_risk Nov. 12 at 10:27 PM

$ANTX - AN2 Therapeutics, Inc. - 10Q - Updated Risk Factors ANTX’s 10-Q risk factors now stress its early-stage pipeline with no clinical proof of concept, recent clinical trial failures and epetraborole discontinuation, major financial losses, August 2024 restructuring, expanded funding and operational risks, heightened IP and regulatory hurdles, new international and compliance challenges, and increased stock price volatility and delisting risks. #Biotechnology #RegulatoryChallenges #FinancialLosses #ClinicalTrialRisks #EarlyStagePipeline 🟢 Added 🟠 Removed https://d-risk.ai/ANTX/10-Q/2025-11-12

0 · Reply

Elrabino Nov. 10 at 3:37 PM

$ANTX Getting found on partnership news. Heating up with almost 10x daily volume $INTS $RUBI $MODD

0 · Reply

mebanks Nov. 10 at 1:56 PM

$ANTX , good partnership, expected some more price movement

0 · Reply

Candyfan Nov. 10 at 1:02 PM

$ANTX - this should run with GLTO

0 · Reply

TA_Kongen Nov. 10 at 1:02 PM

$ANTX Gates Foundation recurring funding - GSK news, might be some recycle but still. Good chance for a move here.

0 · Reply

AN2 Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business and Scientific Highlights

Nov 10, 2025, 7:00 AM EST - 2 months ago

AN2 Therapeutics Announces Research Collaboration With GSK to Advance Boron-Based LeuRS-Inhibitors Targeting Tuberculosis (TB)

Nov 6, 2025, 5:03 PM EST - 2 months ago

AN2 Therapeutics to Participate in Fireside Chat at Evercore HealthCONx Conference

Aug 12, 2025, 4:01 PM EDT - 5 months ago

AN2 Therapeutics Reports Second Quarter 2025 Financial Results and Recent Business and Scientific Highlights

Aug 12, 2025, 7:00 AM EDT - 5 months ago

AN2 Therapeutics Commences First-in-Human Clinical Trial of Oral AN2-502998 for Chagas Disease

Jul 23, 2025, 7:00 AM EDT - 6 months ago

AN2 Therapeutics and DNDi Collaborate on Clinical Development of Promising New Oral Compound to Treat Chronic Chagas Disease

Jun 30, 2025, 7:00 AM EDT - 6 months ago

AN2 Therapeutics Reports Key Insights from 200-Patient Observational Study in Acute Melioidosis, Laying Groundwork for Phase 2 Proof-of-Concept Trial of Epetraborole

May 29, 2025, 7:00 AM EDT - 8 months ago

AN2 Therapeutics Announces Poster Presentation Highlighting M. Abscessus Data at 2025 Colorado Mycobacteria Conference

May 13, 2025, 4:01 PM EDT - 8 months ago

AN2 Therapeutics Reports First Quarter 2025 Financial Results and Recent Business and Scientific Highlights

May 1, 2025, 4:00 PM EDT - 8 months ago

AN2 Therapeutics Reports Data from the Phase 3 Portion of Previously Terminated EBO-301 Study and Outlines Future Milestones from Boron Chemistry Pipeline

Apr 30, 2025, 7:00 AM EDT - 9 months ago

AN2 Therapeutics to Participate in Citizens JMP Life Sciences Conference

Mar 25, 2025, 4:00 PM EDT - 10 months ago

AN2 Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business and Scientific Highlights

Mar 3, 2025, 4:00 PM EST - 11 months ago

AN2 Therapeutics to Present at Leerink Partners Global Healthcare Conference

$AN2 Provides Strategic Update for Phase 3 EBO-301 Trial in Treatment Refractory MAC Lung Disease$

Feb 24, 2025, 7:00 AM EST - 11 months ago

AN2 Provides Strategic Update for Phase 3 EBO-301 Trial in Treatment Refractory MAC Lung Disease

Feb 20, 2025, 7:00 AM EST - 11 months ago

AN2 Therapeutics to Participate at Upcoming Investor Conferences

Jan 29, 2025, 4:00 PM EST - 1 year ago

AN2 Therapeutics to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference

Nov 13, 2024, 4:00 PM EST - 1 year ago

AN2 Therapeutics Reports Third Quarter 2024 Financial Results, Provides Important EBO-301 Update and Highlights Progress Across Boron Chemistry Pipeline

Oct 17, 2024, 7:00 AM EDT - 1 year ago

AN2 Therapeutics Receives Continuation Grant to Discover Novel Boron Based Therapies for Tuberculosis (caused by Mycobacterium tuberculosis) and Malaria

Aug 28, 2024, 4:00 PM EDT - 1 year ago

AN2 Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Aug 16, 2024, 7:00 AM EDT - 1 year ago

AN2 Therapeutics Adopts Limited Duration Stockholder Rights Plan

Aug 13, 2024, 4:01 PM EDT - 1 year ago

AN2 Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business and Scientific Highlights

$AN2 Therapeutics Provides Update on EBO-301 Phase 2/3 Study Evaluating Epetraborole for Treatment-Refractory Mycobacterium avium Complex (MAC) Lung Disease$

Aug 8, 2024, 4:30 PM EDT - 1 year ago

AN2 Therapeutics Provides Update on EBO-301 Phase 2/3 Study Evaluating Epetraborole for Treatment-Refractory Mycobacterium avium Complex (MAC) Lung Disease

May 14, 2024, 4:01 PM EDT - 1 year ago

AN2 Therapeutics Reports First Quarter 2024 Financial Results and Recent Business and Scientific Highlights

Mar 28, 2024, 4:10 PM EDT - 1 year ago

AN2 Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business and Scientific Highlights

Feb 12, 2024, 6:56 AM EST - 2 years ago

AN2 Therapeutics to pause lung disease study enrollment

$AN2 to Voluntarily Pause Enrollment in Phase 3 Part of Phase 2/3 Pivotal Clinical Trial Evaluating Epetraborole for Treatment-Refractory Mycobacterium Avium Complex (MAC) Lung Disease$

Feb 12, 2024, 6:45 AM EST - 2 years ago

AN2 to Voluntarily Pause Enrollment in Phase 3 Part of Phase 2/3 Pivotal Clinical Trial Evaluating Epetraborole for Treatment-Refractory Mycobacterium Avium Complex (MAC) Lung Disease

Jan 30, 2024, 4:10 PM EST - 2 years ago

AN2 Therapeutics to Present at Oppenheimer Healthcare Life Sciences Conference

Nov 9, 2023, 4:05 PM EST - 2 years ago

AN2 Therapeutics Reports Third Quarter 2023 Financial Results and Recent Business and Scientific Highlights

Nov 6, 2023, 7:00 AM EST - 2 years ago

AN2 Therapeutics to Present at Upcoming Investor Conferences

Oct 18, 2023, 7:00 AM EDT - 2 years ago

AN2 Therapeutics Signs License Agreement with the University of Georgia Research Foundation to Develop Novel Boron-Based Therapy for Chagas Disease

Oct 11, 2023, 12:01 AM EDT - 2 years ago

AN2 Therapeutics to Present New Data for Epetraborole at IDWeek 2023

Sep 26, 2023, 7:00 AM EDT - 2 years ago

AN2 Therapeutics Signs Grant Agreement to Discover Novel, Boron Based Therapies for Tuberculosis and Malaria

$AN2 Therapeutics commences Phase 3 Part of Phase 2/3 Clinical Trial Evaluating Epetraborole for Treatment-Refractory Mycobacterium avium complex (MAC) Lung Disease$

Sep 13, 2023, 7:00 AM EDT - 2 years ago

AN2 Therapeutics commences Phase 3 Part of Phase 2/3 Clinical Trial Evaluating Epetraborole for Treatment-Refractory Mycobacterium avium complex (MAC) Lung Disease

Aug 15, 2023, 10:42 PM EDT - 2 years ago

AN2 Therapeutics Announces Pricing of $70.0 Million Underwritten Offering of Common Stock

Aug 10, 2023, 4:10 PM EDT - 2 years ago

AN2 Therapeutics Reports Second Quarter 2023 Financial Results and Recent Highlights

May 25, 2023, 4:10 PM EDT - 2 years ago

AN2 Therapeutics to Present at Jefferies Healthcare Conference

May 11, 2023, 4:10 PM EDT - 2 years ago

AN2 Therapeutics Reports First Quarter 2023 Financial Results and Recent Highlights

May 5, 2023, 1:55 PM EDT - 2 years ago

AN2 Therapeutics: Boron Chemistry For Infectious Diseases

May 1, 2023, 7:00 AM EDT - 2 years ago

AN2 Therapeutics to Present at JMP Securities Life Sciences Conference

Mar 29, 2023, 4:01 PM EDT - 3 years ago

AN2 Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Highlights

Feb 28, 2023, 4:10 PM EST - 3 years ago

AN2 Therapeutics to Participate in Upcoming Investor Conferences

Jan 31, 2023, 4:10 PM EST - 3 years ago

AN2 Therapeutics to Present at SVB Securities Global Biopharma Conference

Nov 9, 2022, 4:05 PM EST - 3 years ago

AN2 Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Updates

Oct 19, 2022, 8:00 AM EDT - 3 years ago

AN2 Therapeutics to Present New Epetraborole Data at IDWeek 2022

OfficialStocktwitsUser Jan. 6 at 4:40 AM

0 · Reply

SuperGreenToday Dec. 31 at 5:52 PM

$ANTX

0 · Reply

SprintShares Dec. 26 at 4:58 PM

0 · Reply

TheRealShortSqueezy Dec. 15 at 3:26 PM

1 · Reply

TheRealShortSqueezy Dec. 15 at 1:47 PM

0 · Reply

d_risk Nov. 12 at 10:27 PM

0 · Reply

Elrabino Nov. 10 at 3:37 PM

$ANTX Getting found on partnership news. Heating up with almost 10x daily volume $INTS $RUBI $MODD

0 · Reply

mebanks Nov. 10 at 1:56 PM

$ANTX , good partnership, expected some more price movement

0 · Reply

Candyfan Nov. 10 at 1:02 PM

$ANTX - this should run with GLTO

0 · Reply

TA_Kongen Nov. 10 at 1:02 PM

$ANTX Gates Foundation recurring funding - GSK news, might be some recycle but still. Good chance for a move here.

0 · Reply

JL_TradeZ Nov. 10 at 12:22 PM

$ANTX off to a strong start this morning after the GSK collaboration and renewed Gates Foundation funding hit the wire. Volume’s already heating up, and it’s holding above the 50-day MA with all EMAs curling up. If it can stay above 1.25–1.28 and break through 1.35 with more volume, it could make a clean move toward 1.50–1.70. Float’s only around 16M, so it can move fast once momentum builds

0 · Reply

KimAntony Nov. 10 at 12:11 PM

$ANTX big news ... collaboration with GSK - https://www.streetinsider.com/dr/news.php?id=25581523

0 · Reply

Bullish_Trader555 Nov. 10 at 12:05 PM

$ANTX AN2 Therapeutics Announces Research Collaboration With GSK to Advance Boron-Based LeuRS-Inhibitors Targeting Tuberculosis (TB) $GSK $SPY

0 · Reply

Fra1986 Oct. 27 at 7:27 PM

$ANTX strong buy

0 · Reply

Redposition Oct. 15 at 10:40 PM

$ANTX $1.20 forever 😏

0 · Reply

lealbinagor98 Oct. 15 at 12:58 PM

$GOVX coming soon let's up 🚀⏰️🔥 $NVAX $AIM $ANTX

0 · Reply

SmartContent Sep. 23 at 8:23 PM

$ANTX centers on epetraborole, a first-in-class benzoxaborole antibiotic that targets leucyl-tRNA synthetase giving it a novel MOA against NTM lung disease (esp. MAC), where current regimens are long, toxic, and face rising macrolide resistance. If ongoing studies confirm the drug’s efficacy and tolerability, ANTX could pursue accelerated or priority pathways in a high-mortality, orphan-like market with limited competition, enabling premium pricing and durable revenue even at modest penetration. The platform has expansion potential (e.g., other mycobacterial infections), supported by strong IP and a clear biological rationale, which together improve odds of partnerships or a takeout. With a small enterprise value relative to the addressable market, clear positive clinical readouts, de-risked CMC, and a credible path to reimbursement could catalyze a major valuation re-rating.

0 · Reply

papale Sep. 18 at 10:55 AM

$ANTX 4 catalysts this year yet? I'm in!

0 · Reply

BonChonzo Sep. 18 at 9:12 AM

$ANTX 1,34$ finally over 1,32$!

0 · Reply

SmartContent Sep. 15 at 4:22 AM

$PHGE has two shots on goal: BX004, an inhaled phage cocktail for CF lung infections now in Phase 2b with top-line data due Q1 2026, and BX211, a phage therapy for diabetic foot osteomyelitis that showed Phase 2 wound-healing benefit and is moving toward a registrational trial; if either advances smoothly, approval could come around 2028–2030. $ANTX, after its epetraborole MAC program failed, is now leaning on a government-funded melioidosis program (Phase 2 next) and a new oral compound for Chagas disease (Phase 1 in progress, Phase 2 targeted for 2026), giving it cash runway into 2028 but pushing any real commercial shot to 2029 or later.

0 · Reply

Redposition Sep. 12 at 1:20 AM

$ANTX Why the 10% drop AH ?

1 · Reply

BonChonzo Sep. 9 at 2:59 PM

$ANTX what happened?

1 · Reply

Market Cap	30.42M
Revenue (ttm)	0.00
Net Income (ttm)	-51.32M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	68,700
Avg Vol	72,936
Day's Range	N/A - N/A
Shares Out	27.40M
Stochastic %K	67%
Beta	-0.03
Analysts	Sell
Price Target	$1.50